Showing 4511-4520 of 7517 results for "".
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- Fibrocell and Intrexon: Highlights of Pre-Clinical Data for Potential First-in-Class Treatment for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-and-intrexon-highlights-of-pre-clinical-data-for-potential-first-in-class-treatment-for-recessive-dystrophic-epidermolysis-bullosa/2458847/Fibrocell Science, Inc., and Intrexon Corporation are highlighting a poster entitled “Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)” being presented at the American Society of
- Syneron Introduces PicoWay Resolvehttps://practicaldermatology.com/news/syneron-introduces-picoway-resolve/2458850/Syneron Medical Ltd. introduced the PicoWay Resolve™, a dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve frac
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/secukinumab-phase-iii-data-confirm-significant-efficacy-in-patients-with-psoriatic-arthritis/2458858/Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a Phase III
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- Cynosure to Host Investor Event to Introduce SculpSurehttps://practicaldermatology.com/news/cynosure-to-host-investor-event-to-introduce-sculpsure/2458877/Cynosure, Inc. will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure™, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to